+23.5%
GSK vs UPRO
+43.9%
-20.5%
-18.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | UPRO | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -1.4% | +1.6% | +0.3% |
| 7D | -3.6% | -1.3% | -2.3% | -3.5% |
| 30D | -5.9% | -5.0% | -0.9% | -5.5% |
| 3M | -4.3% | +7.5% | -11.7% | -5.1% |
| 6M | -10.8% | +33.2% | -44.0% | -15.0% |
| YTD | +1.8% | +27.7% | -25.9% | -2.8% |
| 1Y | +23.5% | +43.0% | -19.6% | +8.3% |
| All | +23.5% | +43.9% | -20.5% | +8.3% |
Cumulative growth
Daily Returns
Daily percentage return beside UPRO.
Daily Out/Under-Performance
Portfolio return minus UPRO return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × UPRO return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded UPRO wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling